Comparison Overview
Interpace Biosciences

Interpace Biosciences
300 Interpace Pkwy, Parsippany, New Jersey, 07054, US
Last Update: 25/02/2026
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Interpace Diagnostics is a fully integr...

bioMérieux
100, Allée Louis Pasteur, Marcy-l'Étoile, 69280, FR
Last Update: 01/04/2026
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been pavin...
Compliance Ranges Comparison

Interpace Biosciences







bioMérieux






Benchmark & Cyber Underwriting Signals
Incidents vs Biotechnology Research Industry Avg (This Year)
No incidents recorded for Interpace Biosciences in 2026.
Incidents vs Biotechnology Research Industry Avg (This Year)
No incidents recorded for bioMérieux in 2026.
Incident History - Interpace Biosciences (X = Date, Y = Severity)
Interpace Biosciences cyber incidents detection timeline including parent company and subsidiaries.
Incident History - bioMérieux (X = Date, Y = Severity)
bioMérieux cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents

Interpace Biosciences

bioMérieux
FAQ
Latest Global CVEs
PraisonAI before 1.5.115 contains a path traversal vulnerability in MultiAgentMonitor that fails to sanitize agent IDs when building file paths. Attackers can include traversal sequences like ../ in agent IDs to read, write, or overwrite arbitrary files, enabling sensitive disclosure, denial of service, or code execution.
PraisonAI before 1.5.115 contains an information disclosure vulnerability in the MultiAgentLedger component that allows attackers to access sensitive data by registering agents with duplicate IDs. Attackers can exploit the lack of agent ID uniqueness enforcement to share ledger instances and expose system prompts and conversation history between agents.
PraisonAI before 1.5.128 contains a cross-origin agent execution vulnerability in the AGUI endpoint that allows remote attackers to trigger arbitrary agent execution. The POST /agui endpoint lacks authentication and hardcodes Access-Control-Allow-Origin: * headers, combined with Starlette's Content-Type-agnostic JSON parsing, enabling attackers to bypass CORS preflight checks via simple requests and exfiltrate sensitive agent responses including tool execution results and environment data.
PraisonAI before 4.5.128 contains an arbitrary shell command execution vulnerability where the UI modules hardcode approval_mode to auto, overriding administrator configuration from PRAISON_APPROVAL_MODE environment variable. Authenticated attackers can instruct the LLM agent to execute arbitrary shell commands via subprocess.run with shell=True, bypassing the manual approval gate and insufficient command sanitization blocklists.
PraisonAI before 1.5.128 caches tool approval decisions by tool name only, not by invocation arguments, allowing subsequent execute_command calls to bypass approval prompts. Attackers can exploit this by obtaining initial approval for a benign command, then silently exfiltrate API keys and credentials via subsequent shell commands without user consent.